One Shot a Month: What New Trial Data on Pfizer's Next-Generation GLP-1 Injection Mean for You

If you are currently on a weekly GLP-1 injection for weight loss, you already know the routine: a reminder on your phone, a new pen from the pharmacy, and the small but real mental load of never letting a week slip by. Many of my patients tell me that the injection itself isn't the hard part — it's remembering to do it, week after week, month after month, for years. That is exactly the problem a new experimental medicine is trying to solve, and on February 3, 2026, Pfizer announced results that suggest it might. I want to walk you through what was actually shown, because the headlines can make it sound more finished than it is.

What Is This New Medicine?

The drug is called PF-08653944, previously known in earlier research as MET-097i. Like semaglutide (the active ingredient in Wegovy) and tirzepatide (the active ingredient in Mounjaro and Zepbound), it belongs to a class of medicines called GLP-1 receptor agonists. These drugs work by mimicking a natural gut hormone, GLP-1, which slows stomach emptying, reduces appetite, and helps the brain register fullness sooner. Pfizer describes PF-08653944 as "fully-biased," a pharmacology term referring to how selectively the drug activates the GLP-1 receptor's beneficial signaling pathways. What makes it genuinely different from the injectable GLP-1 medicines available today, though, isn't the receptor biology — it's the schedule. After an initial period of weekly dose increases, PF-08653944 is designed to be given as a single injection once a month for ongoing maintenance therapy.

Inside the VESPER-3 Trial

The results come from VESPER-3, a Phase 2b study — meaning it is a mid-stage trial designed mainly to test dosing and gather early efficacy and safety data, not the large, final-stage trial required for approval. It was a 64-week, randomized, double-blind, placebo-controlled trial, the gold-standard design where neither participants nor researchers knew who received the active drug versus placebo until the data were analyzed. Participants were adults with obesity or who were overweight, and did not have type 2 diabetes. Everyone started with weekly injections during a titration phase lasting up to 12 weeks, a gradual dose-escalation approach used with GLP-1 medicines to help the body adjust and limit side effects. After titration, participants transitioned to monthly injections for maintenance, continuing through week 28. The trial tested four different active-treatment dose regimens, each with roughly 54 participants, compared against a placebo group.

What the Results Showed

By week 28, weight loss varied by dose, with a clear dose-response relationship. One treatment arm produced a 10% placebo-adjusted reduction in body weight, while the highest-dose arm achieved a 12.3% placebo-adjusted reduction — meaning participants on that dose lost, on average, 12.3 percentage points more of their body weight than those on placebo. What I find particularly noteworthy for patients is what happened at the transition point: when participants switched from weekly to monthly dosing, weight loss did not plateau or stall. It continued through the rest of the study, which suggests the monthly maintenance schedule was genuinely sustaining the drug's effect rather than just preserving weight already lost.

Safety and What We Still Don't Know

Overall, the medicine was described as well tolerated. The side effects that did occur were predominantly mild-to-moderate gastrointestinal symptoms, particularly nausea, which is consistent with what we see across this entire class of medicines. Severe nausea or vomiting was minimal, and no severe diarrhea was reported. Across both the weekly titration phase and the monthly maintenance phase combined, ten participants discontinued the trial due to adverse events. It's important to be clear-eyed here: this is Phase 2b data from a relatively small number of participants, studied for 28 weeks of active dosing within a 64-week trial. It is investigational — PF-08653944 is not approved by the FDA or any regulatory authority, and it is not available to patients. Before it could reach the market, it would need to go through larger, longer Phase 3 trials, which test the drug in thousands of patients and look more closely at long-term safety, durability of weight loss, and how it performs across more diverse populations.

The Bottom Line

What excites me about this data isn't a dramatic new number — the weight loss percentages are in a similar range to what we already see with existing GLP-1 therapies. What's new is the possibility of achieving that result with roughly 12 injections a year instead of 52 once a patient reaches the maintenance phase. For many people, especially those who struggle with the logistics or anxiety of a weekly injection routine over the long term, that difference in convenience could translate into better adherence and, ultimately, better outcomes sustained over years rather than months. That said, we are still early: this is one mid-stage trial, and larger studies are needed before we know how this medicine compares to what's already available, and before it becomes an option any of us can prescribe. If you're currently managing your weight with a GLP-1 medicine, or considering one, I'd encourage you not to change anything based on this news — but do bring it up at your next visit. Keeping up with where this field is heading is part of how we plan your long-term care together.